Literature DB >> 15550131

Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese.

N M Luk1, L C Ho, C L Choi, K H Wong, K H Yu, W K Yeung.   

Abstract

Cutaneous melanoma is rare among Chinese people. The clinicopathologic features and prognostic factors of 63 Hong Kong ethnic Chinese cases were analysed. We found that the mean age of onset was 65.5 years with a female : male ratio of 1 : 1.33. Forty-two (66.7%) patients had their tumours on their feet. More than 50% had the acral lentiginous histologic subtype. The mean tumour thickness was 5.73 mm with 92.1% (n = 58) having a Clark's level of III or more. Of the tumours, 57.1% were ulcerated. Stage I and II tumours comprised 73% (n = 46) while stage III and IV tumours made up of 26% (n = 17). The 1-, 3- and 5-year survival rates were 75%, 30% and 17%, respectively. Univariate analysis for overall survival showed that advanced clinical staging (stage III and IV), tumour ulceration and thicker tumour (>4 mm) had a significantly poorer prognosis. Multivariate analysis demonstrated that advanced clinical staging was the most decisive prognostic factor followed by tumour ulceration. Our study showed that cutaneous melanoma in Chinese people is a disease predominantly of an older age group with the acral lentiginous histologic type located mainly on the feet. The prognosis depends on clinical staging and ulceration status.

Entities:  

Mesh:

Year:  2004        PMID: 15550131     DOI: 10.1111/j.1365-2230.2004.01644.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  18 in total

1.  Skin cancer in asians: part 2: melanoma.

Authors:  Susun Bellew; James Q Del Rosso; Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2009-10

2.  Melanoma : A Frequently Missed Diagnosis.

Authors:  R Lakhtakia; A Mehta; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.

Authors:  Douglas B Johnson; Chengwei Peng; Richard G Abramson; Fei Ye; Shilin Zhao; Jedd D Wolchok; Jeffrey A Sosman; Richard D Carvajal; Charlotte E Ariyan
Journal:  Oncologist       Date:  2015-05-11

4.  Treatment and outcomes of melanoma in acral location in Korean patients.

Authors:  Mi Ryung Roh; Jihyun Kim; Kee Yang Chung
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

5.  Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP).

Authors:  Minhyung Kim; Asher B Blum; Michelle L Haslinger; Michael J Donahue; Daniel T Fisher; Joseph J Skitzki; Il Young Park
Journal:  Surg Today       Date:  2014-07-08       Impact factor: 2.549

6.  Different progression pattern between acral and nonacral melanoma: A retrospective, comparative, clinicoprognostic study of 492 cases of primary cutaneous melanoma according to tumor site.

Authors:  Joon Min Jung; Chang Jin Jung; Chong Hyun Won; Sung Eun Chang; Mi Woo Lee; Jee Ho Choi; Woo Jin Lee
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 [SEASON]       Impact factor: 2.545

7.  A rare form of melanoma masquerading as a diabetic foot ulcer: a case report.

Authors:  Susan Thomas; Yuan-Xiang Meng; Vijaykumar G Patel; Gregory Strayhorn
Journal:  Case Rep Endocrinol       Date:  2012-04-04

8.  Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature.

Authors:  Ivan R Bristow; Katharine Acland
Journal:  J Foot Ankle Res       Date:  2008-09-15       Impact factor: 2.303

9.  Treatment outcomes of advanced stage malignant melanoma in hand and foot after amputation in Korean patients.

Authors:  Kyujin Cho; Sung Taek Jung
Journal:  Clin Orthop Surg       Date:  2013-11-18

10.  Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma.

Authors:  Yi-Shuan Sheen; Yi-Hua Liao; Ming-Hsien Lin; Hsien-Ching Chiu; Shiou-Hwa Jee; Jau-Yu Liau; Yih-Leong Chang; Chia-Yu Chu
Journal:  PLoS One       Date:  2016-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.